Croda International PLC

CRDA: XLON (GBR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|^<bLOCK|$<%hfLOCK|?<^>^$#

Croda Earnings: Beauty Shines, but Pharma Solutions Continue to Drag; Fair Value Cut by 23%

Croda's organic sales growth accelerated to 9% in constant currency in the second quarter, from 1% previously, driven by strong growth in beauty actives, partially offset by a steep decline in pharma solutions. Adjusted operating margin improved to 17.7%. Shares rose 6% in July 28 trading.

Sponsor Center